Vascular chymase: Pathophysiological role and therapeutic potential of inhibition

Cardiovascular Research

Volumn 61, Issue 4, 2004, Pages 653-662

  Doggrell, Sheila A ^a,b   Wanstall, Janet C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Doggrell Biomedical Communications   (New Zealand)

Author keywords

Angiotensin; Chymase; Chymase inhibitors; Mast cells; Vascular disease

Indexed keywords

3 [(3 AMINO 4 CARBOXY)PHENYLSULFONYL] 7 CHLOROQUINAZOLINE 2,4 (1H,3H) DIONE; 4 [(1 NAPHTHYLMETHYL)BENZIMIDAZOL 2 YLTHIO]BUTANOIC ACID; 4 [1 [[BIS(4 METHYLPHENYL)METHYL]CARBAMOYL] 3 (2 ETHOXYBENZYL) 4 OXO 2 AZETIDINYLOXY]BENZOIC ACID; ALPHA 1 ANTITRYPSIN; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; CAPTOPRIL; CATHEPSIN G; CHOLESTEROL; CHYMASE; CHYMASE INHIBITOR; CHYMOSTATIN; CILAZAPRILAT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE I; ENALAPRILAT; ENDOTHELIN; HEPARIN; HIGH DENSITY LIPOPROTEIN; LISINOPRIL; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; PROTEINASE; PROTEINASE INHIBITOR; SUN C 8257; TEI E 548; TRANILAST; TRANSFORMING GROWTH FACTOR BETA1; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ADVENTITIA; AGING; ANGIOGENESIS; APOPTOSIS; ASTHMA; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY INJURY; CATALYSIS; CELL PROLIFERATION; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME RELEASE; ENZYME SPECIFICITY; ENZYME STRUCTURE; EXTRACELLULAR FLUID; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAST CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PULMONARY ARTERY DISEASE; RESTENOSIS; REVIEW; SEQUENCE HOMOLOGY; VASOCONSTRICTION;

AGING; ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARTERIOSCLEROSIS; CHYMASES; ENDOTHELIUM, VASCULAR; HUMANS; MAST CELLS; MODELS, ANIMAL; NEOVASCULARIZATION, PATHOLOGIC; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; VASCULAR DISEASES;

EID: 1342281660     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2003.11.029     Document Type: Review

References (64)

1. Urata H., Kinoshita A., Misono K.S., Bumpus F.M., Husain A., et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 265:1990;22348-22357.
2. Caughey G.H. New developments in the genetics and activation of mast cell proteases. Mol. Immunol. 38:2001;1353-1357.
3. Lindstedt L., Lee M., Kovanen P.T. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid. Atherosclerosis. 155:2001;87-97.
4. Caughey G.H., Raymond W.W., Wolters P.J. Angiotensin II generation by mast cell α- and β-chymases. Biochim. Biophys. Acta. 1480:2000;245-257.
5. Sanker S., Chandrasekharen U.M., Wilk D., et al. Distinct multisite synergistic interactions determine substrate specificities of human chymase and rat chymase for angiotensin II formation and degradation. J. Biol. Chem. 272:1997;2963-2968.
6. Urata H., Strobel F., Ganten D. Widespread tissue distribution of human chymase. J. Hypertens. 12:1994;S17-822.
7. Urata H., Healy B., Stewart R.W., Bumpus F.M., Husain A. Angiotensin II-forming pathways in normal and failing human heart. Circ. Res. 66:1990;883-890.
8. Borland J.A., Chester A.H., Morrison K.A., Yacoub M.H. Alternative pathways of angiotensin II production in the human saphenous vein. Br. J. Pharmacol. 125:1998;423-428.
9. Borland J.A., Chester A.H., Rooker S.J., et al. Expression and function of angiotensin converting enzyme, chymase, and angiotensin II in the human radial artery and internal thoracic artery. Ann. Thorac. Surg. 70:2000;2054-2063.
10. Nishimoto M., Takai S., Sawada Y., et al. Chymase-dependent angiotensin ii formation in the saphenous vein versus the internal thoracic artery. J. Thorac. Cardiovasc. Surg. 121:2001;729-734.
11. Akasu M., Urata H., Kinoshita A., Sasaguri M., Ideishi M., Arakawa K. Difference in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension. 32:1998;514-520.
12. Takai S., Sakaguchi M., Jin D., Yamada M., Kirimura K., Miyazaki M. Different angiotensin II-forming pathways in human and rat vascular tissues. Clin. Chim. Acta. 305:2001;191-195.
13. Jin D., Takai S., Yamada M., Sakaguchi M., Miyazaki M. The functional role of chymase and angiotensin converting enzyme in angiotensin I-induced vascular contraction in monkeys, dogs and rats. Jpn. J. Pharmacol. 84:2000;449-454.
14. Padmanabhan N., Jardine A.G., McGrath J.C., Connell J.M. Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries. Circulation. 99:1999;2914-2920.
15. Vartio T., Seppä H., Vaheri A. Susceptibility of soluble and matrix fibronectins to degradation by tissue proteinases, mast cell chymase and cathepsin G. J. Biol. Chem. 256:1982;471-477.
16. Kofford M.W., Schwartz L.B., Schechter N.M., et al. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272:1997;7127-7131.
17. 84 bond by mast cell chymase. J. Biol. Chem. 268:1994;18134-18140.
18. Leskinen M.J., Lindstedt K.A., Wang Y., Kovanen P.T. Mast cell chymase induced smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler. Thromb. Vasc. Biol. 23:2003;238-243.
19. Wang Y., Shiota N., Leskinen M.J., Lindstedt K.A., Kovanen P.T. Mast cell chymase inhibits smooth muscle cell growth and collagen expression in vitro: transforming growth factor-β1-dependent and -independent effects. Arterioscler. Thromb. Vasc. Biol. 21:2001;1928-1933.
20. Kokkonen J.O., Kovanen P.T. Proteolytic enzymes of mast cell granules degrade low density lipoproteins and promote their granule-mediated uptake by macrophages in vitro. J. Biol. Chem. 264:1989;10749-10755.
21. Lee M., Lindstedt L.K., Kovanen P.T. Mast cell-mediated inhibition of reverse cholesterol transport. Arterioscler. Thromb. 12:1992;1329-1335.
22. Kido H., Nakano A., Okishama N., et al. Human chymase, an enzyme forming novel bioactive 31-amino acid length endothelins. Biol. Chem. 379:1998;885-891.
23. Mizutani H., Schechter N., Lazarua G., Black R.A., Kupper T.S. Rapid and specific conversion of precursor interleukin 1 beta (IL-beta) to an active IL-1 species by human mast cell chymase. J. Exp. Med. 174:1991;821-825.
24. Uehara Y., Urata H., Sasaguri M., et al. Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension. 35:2000;55-60.
25. Takai S., Shiota N., Jin D., Miyazaki M. Functional role of chymase in angiotensin II formation in human vascular tissue. J. Cardiovasc. Pharmacol. 32:1998;826-833.
26. Takai S., Jin D., Sakaguchi M., Miyazaki M. Chymase-dependent angiotensin II formation in human vascular tissue. Circulation. 100:1999;654-658.
27. Nishimura H., Buikema H., Baltatu O., Granten D., Urata H. Functional evidence for alternative ANG II-forming pathways in hamster cardiovascular system. Am. J. Physiol. 275:1998;H1307-H1312.
28. 12)-angiotensin I. Hypertension. 23:1994;857-860.
29. Tom B., Garrelds I.M., Scalbert E., et al. ACE-versus chymase-dependent angiotensin II in human coronary arteries: a matter of efficiency? Arterioscler. Thromb. Vasc. Biol. 23:2003;251-256.
30. Voors A.A., Pinto Y.M., Buikema H., et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br. J. Pharmacol. 125:1998;1028-1032.
31. Petrie M.C., Padmanabhan N., McDonald J.E., Hillier C., Connel J.M., McMurray J.J. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistant arteries for patients with heart failure and coronary heart disease. J. Am. Coll. Cardiol. 37:2001;1056-1061.
32. 12] angiotensin I in human dorsal hand veins. In vivo demonstration of non-ACE production of angiotensin in humans. Circulation. 104:2001;1805-1806.
33. Takai S., Shiota N., Kobayashi S., Matsumara E., Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett. 412:1997;86-90.
34. Wang M., Takagi G., Asai K., et al. Aging increases aortic MMP-2 activity in nonhuman primates. Hypertension. 41:2003;1308-1316.
35. Uehara Y., Urata H., Ideishi M., Arakawa K., Saku K. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc. Res. 55:2002;870-876.
36. Shiota N., Okunishi H., Fukamizu A., et al. Activation of two angiotensin-generating systems in the balloon-injury artery. FEBS Lett. 323:1993;239-242.
37. Miyazaki M., Wada T., Shiota N., Takai S. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intimal hyperplasia after balloon injury. J. Hum. Hypertens. 13(Suppl. 1):1999;S21-S25.
38. Nishimoto M., Takai S., Kim S., et al. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation. 104:2001;1274-1279.
39. Guo C., Ju H., Leung D., Massaeli H., Shi M., Rabinovitch M. A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J. Clin. Invest. 107:2001;703-715.
40. Muramatsu M., Katada J., Hayashi I., Majima M. Chymase as a proangiogenic factor: a possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J. Biol. Chem. 275:2000;5545-5562.
41. Muramatsu M., Katada J., Hattori M., Hayashi I., Majima M. Chymase mediates mast cell-induced angiogenesis in hamster sponge granulomas. Eur. J. Pharmacol. 402:2000;181-191.
42. Katada J., Muramatsu M., Hayashi I., et al. Significance of vascula endothelial cell growth factor up-regulation mediated via a chymase-angiotensin- dependent pathway during angiogenesis in hamster sponge granulomas. J. Pharmacol. Exp. Ther. 302:2002;949-956.
43. Atkinson J.B., Harlan C.W., Harlan G.C., Virmani R. The association of mast cells and atherosclerosis: a morphologic study of early atherosclerotic lesions in young people. Hum. Pathol. 25:1994;154-159.
44. Ihara M., Urata H., Kinoshita A., et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 33:1999;1399-1405.
45. Nishimoto M., Takai S., Fukumoto H., et al. Increased local angiotensin II formation in aneurysmal aorta. Life Sci. 71:2002;2195-2205.
46. Wolny A., Clozel J.-P., Rein J., et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ. Res. 80:1997;219-227.
47. Ohishi M., Ueda M., Rakugi H., et al. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions. J. Hypertens. 17:1999;547-553.
48. Kovanen P.T., Kaartinen M., Paavonen T., et al. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 92:1995;1084-1088.
49. Kaartinen M., Penttila A., Kovanen P.T. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-α Circulation. 94:1996;2787-2792.
50. Ortlepp J.R., Janssens U., Bleckmann F., et al. A chymase gene variant is associated with atherosclerosis in venous coronary artery bypass grafts. Coron. Artery Dis. 12:2001;493-497.
51. Hamada H., Terai M., Kimura H., Hirano K., Oana S., Niimi H. Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease. Am. J. Respir. Crit. Care Med. 160:1999;1303-1308.
52. Jin D., Takai S., Shiota N., Miyazaki M. Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II. Eur. J. Pharmacol. 361:1998;199-205.
53. Shiota N., Okunishi H., Takai S., et al. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation. 99:1999;1084-1090.
54. waf1/cip1/sdi1 and p53. Circ. Res. 84:1999;543-550.
55. Izawa A., Suzuki J., Takahashi W., Amano J., Isobe M. Tranilast inhibits cardiac allograft vasculopathy in association with p21(Waf1/Cip1) expression on neointimal cells in murine cardiac transplantation model. Arterioscler. Thromb. Vasc. Biol. 21:2001;1172-1178.
56. Saiura A., Sata M., Hirata Y., Nagai R., Makuuchi M. Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. Eur. J. Pharmacol. 433:2001;163-168.
57. Tamai H., Katoh K., Yamaguchi T., et al. The impact of tranilast on restenosis after coronary angioplasty: the second tranilast restenosis following angioplasty trial (TREAT-2). Am. Heart J. 143:2002;506-513.
58. Holmes D.R., Savage M., Lablanche J.-M., et al. Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation. 106:2002;1243-1250.
59. Takai S., Yuda A., Jin D., et al. Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett. 467:2000;141-144.
60. Takai S., Jin D., Sakaguchi M., Kirimura K., Miyazaki M. An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Jpn. J. Pharmacol. 86:2001;124-126.
61. Fukami H., Imajo S., Ito A., et al. Substituted 3- phenylsulfonylquinazoline-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase. Drug Des. Discov. 17:2000;69-84.
62. Takai S., Jin D., Nishimoto M., et al. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci. 69:2001;1725-1732.
63. Takai S., Sakonjo H., Fukuda K., et al. A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl-N-[(3, 4-dioxo-1-phenyl-7-(2-pyridyloxy))-2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J. Pharmacol. Exp. Ther. 304:2003;841-844.
64. Muramatsu M., Yamada M., Takai S., Miyazaki M. Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin-dependent pathway in hamster sponge granulomas. Br. J. Pharmacol. 137:2002;554-560.